Greenwich LifeSciences rises as new data widens potential breast cancer drug market

Greenwich Lifesciences

07/04/2026 11:12

** Shares of biotech firm Greenwich LifeSciences GLSI.O rise 3% to $22.59 premarket

** Co says new late-stage trial data shows its experimental breast cancer drug GLSI-100 works regardless of a key genetic marker, widening the pool of eligible patients

** Says the marker, called HLA-A02, had previously limited who could benefit; removing it could double eligible patients in the U.S. and Europe to about 88,000 a year

** Says early data shows an about 80% cut in cancer returning in patients without the marker, similar to earlier results

** Co says it filed new patent claims that could protect the drug until 2045

** Says GLSI-100’s potential annual market could be as much as $10 bln if approved

** As of last close, stock up ~5% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))